Melbourne scientists have developed an injectable alternative to conventional blood thinners, in what researchers are calling a potential game changer for patients at risk of dangerous clotting conditions.
The new treatment has been designed to reduce the likelihood of internal bleeding, one of the most serious complications associated with existing anticoagulant medications.
Current blood thinners, while effective at preventing clots, carry a well-documented risk of causing internal bleeding in patients, a side effect that can prove life-threatening. The Melbourne-developed injectable aims to address that critical drawback.
The development is seen as a significant step forward in anticoagulant therapy, offering a potentially safer option for the many patients who require ongoing treatment to manage clotting risk.
